Merrion's oral cancer drug passes Phase II trial
This article was originally published in Scrip
Executive Summary
Merrion Pharmaceuticals's potential weekly oral bisphosphonate, Orazol (zoledronic acid), is as therapeutically effective as the marketed comparator, monthly intravenous infusions of zoledronic acid, according to Phase II trial results.